Annual report pursuant to Section 13 and 15(d)

Note 25 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)

v3.8.0.1
Note 25 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Tc99m tilmanocept sales revenue $ 9,000 $ 18,000 $ 4,000 $ 9,000 $ 39,601 $ 19,075
Tc99m tilmanocept license revenue 100,000 1,296,000 246,000 254,000 100,000 1,795,625 1,133,333
Tc99m tilmanocept royalty revenue 9,000         9,126
Grant and other revenue 386,000 224,000 512,000 580,000 1,022,000 511,000 917,000 686,000 1,701,311 3,136,408 1,860,953
Gross profit 391,000 224,000 612,000 580,000 975,000 1,821,000 1,166,000 947,000 1,806,786 4,909,374 3,010,135
Operating expenses 3,912,000 2,609,000 5,435,000 3,728,000 4,215,000 2,731,000 3,407,000 4,705,000 15,683,793 15,058,116 21,450,875
Loss from operations (3,521,000) (2,385,000) (4,823,000) (3,148,000) (3,240,000) (910,000) (2,241,000) (3,758,000) (13,877,007) [1] (10,148,742) [1] (18,440,740) [1]
Loss before income taxes (6,371,000) (2,317,000) (4,783,000) (4,319,000)         (17,789,686) (7,377,894) (23,044,597)
Benefit from income taxes 201,000 776,000 1,631,000 1,454,000         4,062,489
Loss from continuing operations (6,170,000) (1,541,000) (3,152,000) (2,865,000) (2,118,000) (1,761,000) (817,000) (2,682,000) (13,727,197) (7,377,894) (23,044,597)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax 2,112,000 151,000 (2,036,000) 88,446,000 (1,764,000) 1,702,000 (5,865,000) (1,004,000) (490,758) (6,931,137) (4,518,938) [2]
Net income (loss) attributable to common stockholders $ (4,058,000) $ (1,390,000) $ (5,188,000) $ 85,581,000 (3,882,000) (59,000) (6,682,000) (3,686,000) $ 74,946,066 $ (14,308,383) $ (27,608,680)
Loss per common share (basic and diluted):                      
Continuing operations (in dollars per share) $ (0.04) [3] $ (0.01) [3] $ (0.02) [3] $ (0.02) [3]         $ (0.08) $ (0.05) $ (0.15)
Discontinued operations (in dollars per share) 0.01 [3] [3] (0.01) [3] 0.55 [3]         0.55 (0.04) (0.03)
Attributable to common stockholders (in dollars per share) (0.03) [3] (0.01) [3] (0.03) [3] 0.53 [3]         0.47 (0.09) (0.18)
Continuing operations (in dollars per share) (0.04) [3] (0.01) [3] (0.02) [3] (0.02) [3]         (0.08) (0.05) (0.15)
Discontinued operations (in dollars per share) 0.01 [3] [3] (0.01) [3] 0.54 [3]         0.53 (0.04) (0.03)
Attributable to common stockholders (in dollars per share) $ (0.03) [3] $ (0.01) [3] $ (0.03) [3] $ 0.52 [3]         $ 0.45 $ (0.09) $ (0.18)
Tc99m tilmanocept sales revenue 9,000 18,000 4,000 9,000 $ 39,601 $ 19,075
Tc99m tilmanocept license revenue 100,000 1,296,000 246,000 254,000 100,000 1,795,625 1,133,333
Grant and other revenue 386,000 224,000 512,000 580,000 1,022,000 511,000 917,000 686,000 1,701,311 3,136,408 1,860,953
Gross profit 391,000 224,000 612,000 580,000 975,000 1,821,000 1,166,000 947,000 1,806,786 4,909,374 3,010,135
Operating expenses 3,912,000 2,609,000 5,435,000 3,728,000 4,215,000 2,731,000 3,407,000 4,705,000 15,683,793 15,058,116 21,450,875
Loss from operations (3,521,000) (2,385,000) (4,823,000) (3,148,000) (3,240,000) (910,000) (2,241,000) (3,758,000) (13,877,007) [1] (10,148,742) [1] (18,440,740) [1]
Loss from continuing operations (6,170,000) (1,541,000) (3,152,000) (2,865,000) (2,118,000) (1,761,000) (817,000) (2,682,000) (13,727,197) (7,377,894) (23,044,597)
Loss from discontinued operations 2,112,000 151,000 (2,036,000) 88,446,000 (1,764,000) 1,702,000 (5,865,000) (1,004,000) (490,758) (6,931,137) (4,518,938) [2]
Net income (loss) attributable to common stockholders $ (4,058,000) $ (1,390,000) $ (5,188,000) $ 85,581,000 $ (3,882,000) $ (59,000) $ (6,682,000) $ (3,686,000) $ 74,946,066 $ (14,308,383) $ (27,608,680)
Loss per common share (basic and diluted) (1):                      
Continuing operations (in dollars per share) [3]         $ (0.01) $ (0.01) $ (0.01) $ (0.02)      
Discontinued operations (in dollars per share) [3]         (0.02) 0.01 (0.03) 0      
Attributable to common stockholders (in dollars per share) [3]         $ (0.03) $ 0 $ (0.04) $ (0.02)      
[1] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[2] Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).
[3] Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.